Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adults; 18 and over~* At least 10 and no more than 30 clinically typical actinic keratoses on the face~Exclusion Criteria:~* Hypertrophic actinic keratoses or other skin lesions on the head that might required excluded treatment during the study~* Known contraindication to treatment with imiquimod or photodynamic therapy~* Condition that would limit compliance, be a potential safety risk, or require therapy with an excluded treatment~* Systemically immunocompromised~* Pregnant or nursing~* Dermatologic disease and/or condition in treatment area that might exacerbated by treatment with imiquimod, cause difficulty with examination, or require therapy with an excluded treatment~* Participation in another clinical study~* Treatment within the past 60 days with:~  * Ultraviolet therapy~ * Systemic immunomodulators~ * Chemotherapeutic or cytotoxic agents~ * Investigational agents~* Treatment on the head within the past 60 days with:~  * Imiquimod~ * Photodynamic therapy~ * Red or blue light source therapy~ * Cryotherapy or chemotherapy~ * Surgical excision or curettage~ * Topical corticosteroids~ * Laser~ * Dermabrasion~ * Chemical peel~ * Topical retinoids~ * Topical 5-fluorouracil~ * Topical pimecrolimus or tacrolimus~ * Topical diclofenac~* Treatment for actinic keratoses on the head within the past 60 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imiquimod & photodynamic therapy (Type: EXPERIMENTAL): Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by one session of photodynamic therapy of the entire face with aminolevulinic acid and blue light
- Imiquimod (Type: ACTIVE_COMPARATOR): Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by observation

Based on this trial design, predict the completion outcome and termination type (if applicable).